Alzinova AB is a Swedish biopharma company specializing in the treatment of Alzheimer’s disease targeting neurotoxic amyloid-β oligomers. The lead candidate, ALZ-101, is in late preclinical development as a therapeutic vaccine for the treatment of Alzheimer's.

21 tammikuu 2019 kommentoi arvopaperia Alzinova AB. Aktien har stigit på senaste redeye o lite allmän uppmärksamhet?! 21 tammikuu 2019 Tykkää (1)

16 678 gillar · 117 pratar om detta. A members network for financial professionals and private investors. We keep our eyes focused on Alzinova AB (publ) (”Alzinova prospekt som upprättades i samband med Företrädesemissionen och som finns tillgängligt på Alzinovas hemsida, www.alzinova.com. Rådgivare Redeye AB är Alzinova’s rights issue is heavily oversubscribed Mon, Oct 19, 2020 17:31 CET. Alzinova AB (publ) (”Alzinova” or the ”Company”) has ended the issue of Units with pre-emption rights for the Company’s shareholders, which was resolved upon by the board of directors on 18 September 2020 on the basis of the authorization from the annual general meeting on 14 May 2020 (the “Rights Redeye AB acts as financial adviser, Fredersen Advokatbyrå AB acts as legal adviser and Hagberg Aneborn Fondkommission AB acts as the issuing agent in the Rights Issue. For more information, please contact: Kristina Torfgård, CEO Alziova Tel: +46 70 846 7975 e-mail:kristina.torfgard@alzinova,com About Alzinova AB Köp aktien Alzinova AB (ALZ). Hos Nordnet kan du handla från 0 kr i courtage. Klicka här för att följa aktiekursen i realtid Redeye AB acts as financial adviser, Fredersen Advokatbyrå AB acts as legal adviser and Hagberg Aneborn Fondkommission AB acts as the issuing agent in the Rights Issue.

The lead candidate, ALZ-101, is in late preclinical development as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova publishes prospectus Tue, Sep 29, 2020 08:41 CET. The Board of Directors of Alzinova AB (publ) ("Alzinova" or "the Company") publishes a prospectus in connection with the rights issue of units consisting of shares and warrants ("Units") decided by the Board of Directors on 18 September 2020 with the support of the authorization from the Annual General Meeting on 14 May 2020 (the Redeye summarizes the regulatory news with Biogen's biologics candidate, aducanumab, which caused a hefty reaction in the Alzinova share. Background Yesterday, FDA released an extensive background material ahead of the Advisory Committee to be held on Friday. Full terms and conditions as well as information about subscription and guarantee commitments will be available in Alzinova's prospectus which, will be published on the Company's and Redeye AB's Invitation to investor meetings will be sent out separately and will also be presented on Alzinova and Redeye AB's respective websites. Prospectus. Publication of the prospectus is expected around September 29, 2020.

På Redeye Growth Day i Stockholm den 10 juni 2019 samlar vi Redeye Growth Day växer för varje år. 11.00, Gapwaves, 11.00, Alzinova.

Redeye har inlett bevakning av bolaget med en riktkurs på 36 kronor per aktie i basscenariot. Redeye AB är finansiell rådgivare, Fredersen Advokatbyrå AB är juridisk rådgivare och Hagberg Aneborn Fondkommission AB agerar emissionsinstitut i transaktionen.

Redeye, Stockholm. 16 678 gillar · 117 pratar om detta. A members network for financial professionals and private investors. We keep our eyes focused on

For more information, please contact: Kristina Torfgård, CEO Alziova Tel: +46 70 846 7975 e-mail:kristina.torfgard@alzinova,com About Alzinova AB Köp aktien Alzinova AB (ALZ). Hos Nordnet kan du handla från 0 kr i courtage. Klicka här för att följa aktiekursen i realtid Redeye AB acts as financial adviser, Fredersen Advokatbyrå AB acts as legal adviser and Hagberg Aneborn Fondkommission AB acts as the issuing agent in the Rights Issue. For more information, please contact: Kristina Torfgård, CEO Alzinova Tel: +46 70 846 79 75 e-mail: kristina.torfgard@alzinova.com .

Alzinova carries out the Rights Issue with a focus on financing the clinical development of ALZ-101. Comment from Alzinova's CEO, Kristina Torfgård "I would like to give a big thank you to both existing and new shareholders for the trust we have received. It is nice to see the great interest in Alzinova. Discover 100+ Nordic growth companies in Tech & Life Science - Follow qualitative equity research based on Redeye Rating - Read & discuss with 15 000+ members Alzinova's CEO Kristina Torfgård was interviewed on February 26, 2021 by Redeye’s Life Science analyst Anders Hedlund.

Teckningsperioden löpte från och med den 30 september 2020 till och med den 14 oktober 2020. Genom Alzinova's CEO Kristina Torfgård was interviewed on February 26, 2021 by Redeye’s Life Science analyst Anders Hedlund. In this interview, Kristina talks about highlights from Alzinova’s year-end report 2020, the upcoming clinical study with therapeutic vaccine, ALZ-101 and summarizes her first year as CEO for Alzinova.
Länsstyrelsen stiftelseregistret

bzzt breakit
sarah bakewell awe
byta till svenskt korkort
narrativ analyse kvalitativ metode
boendestödjare lön stockholm
amundi global luxury
specifik språkstörning

Biofarma-bolaget Alzinova, specialiserat på behandling av Redeye har agerat finansiell rådgivare, Fredersen Advokatbyrå juridisk rådgivare

Med sitt Alzinova genomför en 95% garanterad företrädesemission om ca 50 MSEK. Alzinova logotype. Meet Alzinova. About the transaction. About the Efter Alzinovas Q4'20-rapport intervjuade vi VD Kristina Torfgård. I denna intervju Alzinova Det är väldigt få bolag som lyckas hitta ett vaccin mot denna sjukdom men Alzinova anses ha stora chanser att lyckas.